An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood T cells to specific lysis of carcinoembryonic antigen-positive tumor cells

Citation
A. Hombach et al., An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood T cells to specific lysis of carcinoembryonic antigen-positive tumor cells, INT J CANC, 88(1), 2000, pp. 115-120
Citations number
21
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF CANCER
ISSN journal
00207136 → ACNP
Volume
88
Issue
1
Year of publication
2000
Pages
115 - 120
Database
ISI
SICI code
0020-7136(20001001)88:1<115:AEHCZS>2.0.ZU;2-D
Abstract
Recombinant T-cell receptors with antibody-like specificity for tumor-assoc iated antigens are successfully used to direct the cytolytic activity of T cells toward tumor cells. Clinical application, however, needs to comply wi th the low immunogenicity of the recombinant receptor, efficient gene trans fer into peripheral blood T cells, and enrichment of receptor-grafted cells . Here. we address these issues and describe an entirely humanized immune r eceptor for use in adoptive immunotherapy of colorectal carcinoma. The rece ptor consists of a single-chain antibody (scFv) binding domain specific for carcinoembryonic antigen (CEA), the IgG hinge and CH2/CH3 (Fc) joining reg ion, and the transmembrane and intracellular CD3 zeta signaling chain. To e xpress the receptor in peripheral blood T cells, both GALV envelope and MuL V 4070A pseudotyped retrovirus turned out to be equally efficient, with tra nsduction efficiencies of about 5% to 40%, depending on the lymphocyte dono r. Furthermore, receptor-grafted T cells could be 2- to 6-fold enriched by magnetic activated cell sorting, utilizing an antibody directed to the extr acellular IgG domain of the receptor, Upon co-culture with CEA(+) tumor cel ls, receptor-grafted T cells are specifically and efficiently activated to cytolysis and IFN-gamma secretion, demonstrating their feasibility for the adoptive immunotherapy of CEA(+) carcinomas. (C) 2000 Wiley-Liss, Inc.